- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02858024
A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine
September 5, 2017 updated by: International Partnership for Microbicides, Inc.
A Two-Cohort, Open-Label, Randomised, Three-Period Crossover Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine
A Two-Cohort, Open-Label, Randomised, Three-Period Crossover Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
Participants must meet all the following criteria to be eligible to enroll in the trial:
- Women 18 and ≤ 40 years of age who can give written informed consent;
- Available for all visits and consent to follow all procedures scheduled for the trial;
- Healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy [if indicated]), laboratory evaluations for genital infections (bacterial vaginosis, gonorrhoea, chlamydia, and trichomonas), and laboratory evaluations for haematology and biochemistry;
- HIV-negative as determined by an HIV test at screening;
- On a stable oral contraceptive regimen for at least three months prior to screening;
- Upon pelvic examination at the time of enrollment, the cervix and vagina appear normal as determined by the Investigator/Physician;
- Asymptomatic for genital infections at the time of enrollment (if a woman is diagnosed with any treatable STI, either clinically or by laboratory test at the time of screening, she must have completed treatment before the date of enrollment);
- Willing to refrain from the use of topical vaginal medications, vaginal products or objects, including female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for seven days prior to enrollment and for the duration of the trial;
- Willing to refrain from tampon use during menses for the entire duration of the trial, other than when assigned to Treatment B (Cohort I);
- Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening;
- Willing to refrain from participation in any other research trial for the duration of this trial;
- Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbor contacts (confidentiality to be maintained);
- Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit; Penile-vaginal intercourse Oral contact with her genitalia
- Hepatitis B and C negative at the time of enrollment.
Exclusion Criteria:
Participants who meet any of the following criteria are NOT eligible to enrol in the trial:
- Currently pregnant or had their last pregnancy outcome within three months prior to screening;
- Currently breast-feeding;
- Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening;
- Untreated symptomatic urogenital infections, e.g. urinary tract or other STIs, or other gynaecological conditions such as vaginal itching, pain, or discharge, within two weeks prior to enrollment;
- Have a Grade 2 or higher pelvic examination finding, according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies;
- History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence;
- Current vulvar or vaginal symptoms/abnormalities that could influence the trial results;
- Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation;
- Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection;
- Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies;
- Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment;
- Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone;
- Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition;
- Have undergone a hysterectomy and/or bilateral oophorectomy and/or presented with amenorrhea within 90 days prior to enrollment;
- Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Cohort I
In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE).
During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
|
Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
Other Names:
followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
Other Names:
Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
Other Names:
|
ACTIVE_COMPARATOR: Cohort II
In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE).
During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
|
Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
Other Names:
Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
Other Names:
Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses, when no tampons are used, during a 28-day ring use period.
Time Frame: 28 days
|
To determine the effect of menses on the local and systemic pharmacokinetics (PK) of dapivirine, delivered by the Dapivirine Vaginal Ring-004, in healthy, HIV-negative women
|
28 days
|
Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses, when tampons are used, during a 28-day ring use period.
Time Frame: 28 days
|
To determine the effect of tampon use during menses on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004, in healthy, HIV-negative women.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses when the ring is removed at the onset of menses, and re-inserted after completion of menses for the remainder of a 28-day period.
Time Frame: 28 days
|
To assess the impact on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004 when the ring is removed at the start of menses, and re-inserted after completion of menses.
|
28 days
|
Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses when the ring is removed at the onset of menses, and a new ring inserted after completion of menses
Time Frame: 28 days
|
To assess the impact on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004 when the ring is removed at the start of menses, and a new ring inserted after completion of menses.
|
28 days
|
The residual amounts of dapivirine in used vaginal rings, removed at the onset of menses, where applicable, or on Day 28.
Time Frame: 28 days
|
To assess residual levels of dapivirine in used rings.
|
28 days
|
Safety will be assessed through the reporting of AEs, including SAEs, laboratory safety assessments (haematology, biochemistry, and urinalysis), physical and gynaecological examinations, and vaginal flora and pH assessments during the trial.
Time Frame: 28 days
|
To assess the safety of the Dapivirine Vaginal Ring-004 in healthy, HIV-negative women.
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 12, 2015
Primary Completion (ACTUAL)
April 16, 2016
Study Completion (ACTUAL)
April 16, 2016
Study Registration Dates
First Submitted
July 19, 2016
First Submitted That Met QC Criteria
August 2, 2016
First Posted (ESTIMATE)
August 8, 2016
Study Record Updates
Last Update Posted (ACTUAL)
September 6, 2017
Last Update Submitted That Met QC Criteria
September 5, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IPM 035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Dapivirine Vaginal Ring-004 and no tampons
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedHIV-1-infectionUnited States
-
International Partnership for Microbicides, Inc.Completed
-
International Partnership for Microbicides, Inc.CompletedHIV InfectionsSouth Africa, Uganda
-
International Partnership for Microbicides, Inc.Completed
-
International Partnership for Microbicides, Inc.Tibotec Pharmaceutical LimitedCompleted
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID)CompletedHuman Immunodeficiency VirusUnited States
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV InfectionsMalawi, South Africa, Uganda, Zimbabwe
-
International Partnership for Microbicides, Inc.CompletedHuman Immunodeficiency VirusUnited States
-
International Partnership for Microbicides, Inc.CompletedHuman Immunodeficiency VirusMalawi, South Africa, Uganda, Zimbabwe